awmsg logo



etanercept (Enbrel®)


Reference No. 1437

Publication date:
13/12/2013


Appraisal information

etanercept (Enbrel®) 25 mg powder and solvent for solution for injection
etanercept (Enbrel®) 50 mg solution for injection
etanercept (Enbrel®) 25 mg/ml powder and solvent for solution for injection
etanercept (Enbrel®) 25 mg solution for injection
etanercept (Enbrel®) 10 mg powder and solvent for solution for injection


Company: Pfizer Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 23/10/2013
AWMSG meeting date: 20/11/2013
   
   
Submission Type: Limited Submission
Status: Superseded
Advice No: 3513
Ministerial ratification: 06/12/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Etanercept (Enbrel®) is recommended as an option for use within NHS Wales for the treatment of: •polyarthritis (rheumatoid factor positive or negative) in children aged 2 to < 4 years and extended oligoarthritis in children and adolescents ≥ 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; •psoriatic arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate; •enthesitis-related arthritis in adolescents ≥ 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download